SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Jan 19, 2016

Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: Jan. 19, 2016 · CIK: 0001506251 · Accession: 0001477932-16-008131

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-206903

Date
January 19, 2016
Author
Leonard Mazur
Form
CORRESP
Company
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)

Letter

ctxr_corresp.htmCitius Pharmaceuticals. Inc.

63 Great Road

Maynard, MA 01754

January 19, 2016

EDGAR

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re: Citius Pharmaceuticals, Inc.

Registration Statement on Form S-1

File No. 333-206903

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Citius Pharmaceuticals, Inc. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Time, on January 21, 2016, or as soon thereafter as possible.

The Company hereby acknowledges the following:

·

that should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

·

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

·

the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Citius Pharmaceuticals, Inc.

By: /s/ Leonard Mazur

Leonard Mazur

Chief Executive Officer & President

Show Raw Text
CORRESP
1
filename1.htm

ctxr_corresp.htmCitius Pharmaceuticals. Inc.

63 Great Road

Maynard, MA 01754

January 19, 2016

EDGAR

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

     Re:  Citius Pharmaceuticals, Inc.

  Registration Statement on Form S-1

 File No. 333-206903

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Citius Pharmaceuticals, Inc. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Time, on January 21, 2016, or as soon thereafter as possible.

The Company hereby acknowledges the following:

 ·

 that should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 ·

 the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 ·

 the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 Citius Pharmaceuticals, Inc.

 By: /s/ Leonard Mazur

 Leonard Mazur

 Chief Executive Officer & President